Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Taselisib in Overgrowth
NCT03290092 · Centre Hospitalier Universitaire Dijon · PHASE1/PHASE2 · terminated · last registry update 2026-02-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “In accordance with the protocol, following the occurrence of two SUSARs, the TOTEM trial was stopped early for safety reasons.” | – | Registry record, Centre Hospitalier Universitaire Dijon |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, Abemaciclib + PI3K Inhibitor paxalisib (NCT03994796)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-02-13Also stopped (suspended): Dana-Farber Cancer Institute, Palbociclib + Gedatolisib (NCT03065062)
- 2025-09-08Also stopped (terminated): Institut Curie, PF-05212384 (NCT02438761)
- 2025-03-24Results posted on the registry: Kazia Therapeutics Limited, Paxalisib (GDC-0084) (NCT03522298)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision